Home  /  About  /  Our Company

Our Company

Company Overview

Six decades at the forefront of API manufacturing.

Founded in 1960 and listed on the NSE and BSE, Anuh Pharma Ltd. is one of India's most established manufacturers of Active Pharmaceutical Ingredients — and part of the INR 8.5 billion SK Group.

A leading producer of Macrolides and Anti-TB APIs — with growing strength in Anti-Bacterials, Anti-Malarials, Anti-Diabetics and Corticosteroids — every batch is made under strict cGMP controls, backed by USFDA, EDQM/EU-GMP, WHO-PQ and CEP approvals, and trusted across 57+ countries.

2400 MTPA
Manufacturing Capacity
57+
Territories Covered
60+
Years of Experience
450+
Satisfied Employees
Our Purpose

Vision, mission & values.

Vision

To carve a niche on the global map through traditional wisdom and values, reposing the faith of our customers, staff and shareholders.

Mission

To manufacture Active Pharmaceutical Ingredients of consistent quality, reliability and safety for customers across the world.

Values

Quality-driven manufacturing, customer focus and strong ethics — the principles that have guided Anuh since 1960.

Timeline History

Our journey since 1960.

1960
  • Company established; registered on the Bombay Stock Exchange (BSE)
1989
  • Commenced manufacturing of Erythromycin salts — 150 MTPA
1995
  • Doubled installed capacity to 300 MTPA
2006
  • Doubled installed capacity to 600 MTPA
2010
  • Received Eu-GMP & CEP for Erythromycin, EES & Pyrazinamide
2012
  • WHO-PQ for Pyrazinamide
  • Acquired R&D centre at Mahape; DSIR recognition
2015
  • Received WHO-PQ for Sulfadoxine
2017
  • Consent to Establish for 2,000 MTPA additional capacity
2019
  • Cleared USFDA inspection
  • Cleared joint EDQM, Eu-GMP & WHO-PQ inspection
  • Inaugurated new expansion — 900 MTPA across 20 products
2021
  • Received CEP for Azithromycin & Gliclazide
2023
  • Received CEP for Allopurinol
2024
  • Listed on the National Stock Exchange (NSE)
  • 4th capacity expansion of 400 MTPA — total 2,200 MTPA
  • Cleared WHO-PQ inspection (WHO, Geneva)
  • Received CEP for Sulfadimethoxine
2026
  • Cleared USFDA inspection with zero 483 observations
  • Cleared EDQM & Eu-GMP inspection (AEMPS, Spain)
  • 5th capacity expansion of 200 MTPA — total 2,400 MTPA
  • Received WHO-PQ (CPQ) for Amodiaquine Hydrochloride
  • Awarded the EcoVadis Bronze Medal for sustainability
← Drag, scroll or use the arrows to explore →